Jazz Pharmaceuticals plc (JAZZ): Results of Operations and Financial Condition
Jazz Pharmaceuticals plc (JAZZ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02. Results of Operations and Financial Condition. Estimated Q3 Financial Impacts Related to the Actio Biosciences, Inc. Acquisition In connection with its acquisition of Actio Biosciences, Inc., a Delaware corporation (“Actio”), which was completed on September 15, 2026,
How this was made
The 30-second read
Why it matters
The disclosed charge is sizable and non‑tax‑deductible, likely prompting a negative price reaction.
Market read
Direct impact on Jazz Pharma's earnings; sector peers may be re‑priced on acquisition risk.
What to watch
Potential tax credits or future cost synergies from Actio could mitigate the charge.
Jazz estimates an approximately $755 million acquired IPR&D charge from the Actio acquisition, with an approximately $11.00 unfavorable impact to both GAAP EPS and non-GAAP adjusted EPS.
The filing provides only preliminary acquisition-related charge estimates and no revenue, profitability, cash flow, balance sheet, segment, or finalized EPS results for the third quarter of 2026.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Estimated acquired in-process research and development expense for the third quarter of 2026GAAP | approximately $755 million | – | – |
| Estimated unfavorable impact to GAAP earnings per share for the third quarter of 2026GAAP | approximately $11.00 | – | – |
| Estimated unfavorable impact to non-GAAP adjusted EPS for the third quarter of 2026non-GAAP | approximately $11.00 | – | – |
What drove it
- The Actio Biosciences, Inc. acquisition was completed on September 15, 2026.
- Jazz currently estimates that its GAAP and non-GAAP financial results for the third quarter of 2026 will include acquired in-process research and development expense.
- The expected IPR&D charge is not tax deductible.
Concerns
- Third-quarter results have not been finalized and remain subject to the Company’s financial statement closing procedures.
- The Company stated that actual results could differ, perhaps materially, from the preliminary estimates.
- The approximately $755 million IPR&D charge is expected to create an approximately $11.00 unfavorable impact to both GAAP EPS and non-GAAP adjusted EPS.
- The filing does not provide the information necessary for a complete understanding of results for the quarter ended September 30, 2026.
What to watch
- Finalized third-quarter financial results for the quarter ended September 30, 2026.
- The final amount of acquired IPR&D expense related to the Actio acquisition.
- The final impact of the Actio-related charge on GAAP EPS and non-GAAP adjusted EPS.
Analysis
This is not a full earnings release. Jazz disclosed preliminary estimated financial impacts from its acquisition of Actio Biosciences, Inc., completed on September 15, 2026, rather than reporting finalized operating results for the third quarter of 2026.
The central disclosed item is a pre-tax charge of approximately $755 million of acquired in-process research and development expense. Jazz expects this charge to be included in both its GAAP and non-GAAP financial results for the third quarter of 2026. The Company stated that the charge is not tax deductible.
Jazz estimates that the IPR&D charge will have an unfavorable impact of approximately $11.00 to both GAAP earnings per share and non-GAAP adjusted EPS. The filing provides no reported revenue, product or segment performance, gross margin, operating income, net income, share count, or finalized EPS, so it does not establish the underlying operating performance of the period.
The filing also contains no cash flow, cash balance, debt, capital-return, or forward-guidance information. Accordingly, the principal issue for investors is the final accounting and EPS effect of the Actio acquisition once Jazz completes its financial statement closing procedures.
Management explicitly stated that results for the quarter ended September 30, 2026 have not been finalized and that actual results may differ, perhaps materially, from the preliminary estimated information. The full condensed consolidated financial statements will be needed to assess revenue trends, operating profitability, cash flow, capital structure, and the final GAAP and non-GAAP reconciliation.
Not in the filing
stated, not guessed- Total revenue
- Revenue prior-year comparison
- Revenue prior-quarter comparison
- Revenue growth rates
- Segment revenue and segment comparisons
- Gross profit and gross margin
- Operating expenses
- Operating income
- Net income or loss
- Final GAAP EPS
- Final non-GAAP adjusted EPS
- Weighted-average diluted shares outstanding
- Product sales metrics
- Operating cash flow
- Free cash flow
- Cash and cash equivalents
- Debt
- Share repurchases
- Dividends
- Forward revenue guidance
- Forward gross-margin guidance
- Forward operating-expense guidance
- Forward tax-rate guidance
- Prior-period outlook for comparison
- Named executive quotations
- Final reconciliation of non-GAAP adjusted EPS to GAAP EPS
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Jazz Pharmaceuticals filed an 8‑K reporting its Q3 financial impact from the recent Actio Biosciences acquisition.
Ticker impact
Jazz Pharma disclosed a $755M pre‑tax IPR&D charge from its Actio acquisition, lowering Q3 GAAP and non‑GAAP EPS by about $11 per share.
downward pressure as investors price in the $11 EPS hit
Material $755M charge directly reduces EPS; market typically reacts negatively to such earnings downgrades.
Market effects
Biopharma earnings outlook may be weighed down by acquisition-related IPR&D charges.
European biotech stocks could see modest pullback.
Limited to pharma sector; no broad market effect.
Counterpoint
If the acquisition accelerates pipeline growth, the long‑term upside may outweigh the short‑term EPS hit.
Key entities
- companyJazz Pharmaceuticals plc
Issuer of the 8‑K filing.
- companyActio Biosciences, Inc.
Acquired entity whose IPR&D is being charged.
